Department of Medical Biotechnology, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.
Department of Molecular Medicine, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.
Appl Microbiol Biotechnol. 2023 Feb;107(2-3):769-783. doi: 10.1007/s00253-022-12322-1. Epub 2022 Dec 20.
Recombinant Chinese hamster ovary (CHO) cell line development for complex biotherapeutic production is conventionally based on the random integration (RI) approach. Due to the lack of control over the integration site and copy number, RI-generated cell pools are always coupled with rigorous screening to find clones that satisfy requirements for production titers, quality, and stability. Targeted integration into a well-defined genomic site has been suggested as a possible strategy to mitigate the drawbacks associated with RI. In this work, we employed the CRISPR-mediated precise integration into target chromosome (CRIS-PITCh) system in combination with the Bxb1 recombinase-mediated cassette exchange (RMCE) system to generate an isogenic transgene-expressing cell line. We successfully utilized the CRIS-PITCh system to target a 2.6 kb Bxb1 landing pad with homology arms as short as 30 bp into the upstream region of the S100A gene cluster, achieving a targeting efficiency of 10.4%. The platform cell line (PCL) with a single copy of the landing pad was then employed for the Bxb1-mediated landing pad exchange with an EGFP encoding cassette to prove its functionality. Finally, to accomplish the main goal of our cell line development method, the PCL was applied for the expression of a secretory glycoprotein, human recombinant soluble angiotensin-converting enzyme 2 (hrsACE2). Taken together, on-target, single-copy, and stable expression of the transgene over long-term cultivation demonstrated our CRIS-PITCh/RMCE hybrid approach might possibly improve the cell line development process in terms of timeline, specificity, and stability. KEY POINTS: • CRIS-PITCh system is an efficient method for single copy targeted integration of the landing pad and generation of platform cell line • Upstream region of the S100A gene cluster of CHO-K1 is retargetable by recombinase-mediated cassette exchange (RMCE) approach and provides a stable expression of the transgene • CRIS-PITCh/Bxb1 RMCE hybrid system has the potential to overcome some limitations of the random integration approach and accelerate the cell line development timeline.
用于复杂生物治疗生产的重组中国仓鼠卵巢 (CHO) 细胞系开发通常基于随机整合 (RI) 方法。由于缺乏对整合位点和拷贝数的控制,RI 产生的细胞池总是伴随着严格的筛选,以找到满足生产滴度、质量和稳定性要求的克隆。将靶向整合到定义明确的基因组位点已被提议作为减轻与 RI 相关的缺点的一种可能策略。在这项工作中,我们结合 CRISPR 介导的精确整合到靶染色体 (CRIS-PITCh) 系统和 Bxb1 重组酶介导的盒交换 (RMCE) 系统,生成了一个同基因表达转基因的细胞系。我们成功地利用 CRIS-PITCh 系统将一个 2.6 kb 的 Bxb1 着陆垫靶向到 S100A 基因簇上游区域,同源臂短至 30 bp,靶向效率为 10.4%。然后,使用带有单个着陆垫的平台细胞系 (PCL) 通过 Bxb1 介导的着陆垫交换与 EGFP 编码盒,证明其功能。最后,为了完成我们的细胞系开发方法的主要目标,将 PCL 应用于分泌糖蛋白人重组可溶性血管紧张素转换酶 2 (hrsACE2) 的表达。总之,在长期培养过程中转基因的靶向、单拷贝和稳定表达表明,我们的 CRIS-PITCh/RMCE 杂交方法可能在时间、特异性和稳定性方面改善细胞系开发过程。关键点:• CRIS-PITCh 系统是一种高效的着陆垫单拷贝靶向整合方法,可用于生成平台细胞系。• CHO-K1 的 S100A 基因簇上游区域可通过重组酶介导的盒交换 (RMCE) 方法重新靶向,并为转基因的稳定表达提供支持。• CRIS-PITCh/Bxb1 RMCE 杂交系统有可能克服随机整合方法的一些局限性并加速细胞系开发的时间表。